Funding & Investment

ADAR1 Capital Management is an Austin-based investment manager focused on public and private equity investments in life sciences and biotechnology. Public adviser and investor materials point to a specialist healthcare and biotech orientation. ADAR1's relevance to psychedelic medicine is source-backed through atai's 2025 private placement. The record is useful for mapping public-market and crossover healthcare capital around psychedelic mental-health drug development.

AIM Youth Mental Health is a US non-profit foundation founded in 2014 that funds scientific research and youth-led participatory action research to improve mental health outcomes for young people. The organization funds psilocybin research—including a study on how psilocybin affects genetic aging markers in young adults with stress-related disorders—alongside fellowships for postdoctoral youth mental health innovators.

ARTIS Ventures is a San Francisco venture capital firm focused on frontier technologies at the intersection of life science, health, and advanced computing. Its current public language emphasizes resilience, TechBio, and backing companies that reshape human health and related systems. ARTIS is a strong psychedelic-adjacent investor record because it has direct exposure to Delix Therapeutics and publicly hosts Delix within its portfolio. It should be described as a techbio and healthcare VC with a source-backed neuroplastogen investment, not as a dedicated psychedelic investor.

Able Partners is a New York City-based venture capital firm focused on early-stage consumer companies in health and wellness, with a stated emphasis on improving everyday life and wellbeing. The firm’s team page describes its partners as active investors in early-stage consumer and healthcare businesses, and its public materials frame the firm’s thesis around “positive living” and closing the wellness gap. In the psychedelic ecosystem, Able Partners is relevant because its public portfolio and investment themes include mental health, substance-use treatment, and companies building around psychedelic-adjacent care delivery. Its website also shows involvement with atai Life Sciences and Compass Pathways, suggesting exposure to the psychedelic mental-health stack alongside broader healthcare and consumer wellness bets.

Adage Capital Management is a Boston-based institutional investment manager with deep roots in public equity investing and selective private-company participation. It is not publicly positioned as a psychedelics specialist. Its relevance to psychedelic medicine comes from confirmed exposure to Beckley Psytech and the 2025 atai/Beckley transaction financing. The record is strongest when framed as broad institutional healthcare capital entering the space opportunistically.

Aja Ventures is a Canadian investment company associated with venture investing in plant medicine, technology, and wellness, with a stated emphasis on early-stage ventures developing psychedelic medicine. Public-facing profiles also describe it as a venture capital fund or investment company connected to psychedelic-adjacent healthcare and longevity themes. It matters in the psychedelic ecosystem because its stated strategy includes backing early-stage psychedelic therapy and drug-discovery efforts, alongside related areas like genetic testing, functional medicine, and personalized healthcare. Public profile sources also point to investments or strategic exposure in companies tied to natural psychedelic medicines and plant-based wellness.

The Alexander Mosley Charitable Trust is a UK philanthropic foundation established in 2011 by Max Mosley in memory of his son, providing proactive grant-making to mental health and psychedelic research causes. The Trust is a principal funder of Imperial College London's Centre for Psychedelic Research, donating over £600,000 to support landmark psilocybin studies published in the New England Journal of Medicine and Nature Medicine.

Ally Bridge Group is a global healthcare investment management firm investing across private and public life-science markets. Its website emphasizes cross-market healthcare investing, with teams and offices spanning New York and Hong Kong. Within psychedelic medicine, Ally Bridge is relevant through atai's 2025 private placement. This makes it a healthcare crossover investor in the sector, not a dedicated psychedelic investor.

Ambria Capital is a venture capital firm that focuses on early-stage companies in mental health and technology, with a stated current emphasis on psychedelic therapies and technologies. The firm says it invests its own money and can fund companies at any stage and in any amount, and its leadership includes founder Michael Sobeck and managing partner Cody Shandraw. The firm matters in the psychedelic ecosystem because it explicitly backs psychedelic therapies and technologies and describes itself as one of the more active investors in the space. Its website and related public materials point to investments and support across the industry, including companies such as Wesana Health, and it has also been associated with broader neurowellness and brain-health investing through Phyto Partners.

The American Foundation for Suicide Prevention (AFSP) is the largest non-profit funder of suicide prevention research in the United States, supporting scientific research, survivor outreach, education programs, and advocacy to reduce loss of life from suicide. AFSP has cited emerging psychedelic research—including psilocybin and ketamine studies—among promising avenues for reducing suicidal ideation, reflecting the growing overlap between suicide prevention and psychedelic-assisted therapy.

The Anne and Don Fizer Foundation is a Houston, Texas-based private charitable foundation established in memory of estate planning attorney Don E. Fizer (1942–2011) and his wife Anne, supporting philanthropy in healthcare and medical research. The foundation has contributed to psychedelic research initiatives, participating in the growing wave of private philanthropic funding for clinical studies of psychedelic-assisted therapy in the United States.

Apeiron Investment Group is a discretionary investment firm founded and owned by Christian Angermayer. Its website says it manages approximately $7 billion and operates with teams in New York, London, Berlin, Abu Dhabi, and Malta, with a primary focus on the U.S. market. It matters in the psychedelic ecosystem because Apeiron has been a recurring backer of atai Life Sciences, including co-leading atai's $125 million Series C financing in 2020 and its $50 million private placement financing in 2025. Apeiron's own website also describes psychedelics as a key part of its investment story and says it has been instrumental in the renaissance of psychedelics as treatments for mental health issues.

Apollo Projects is a venture platform associated with moonshot-style company building and early investments. Public sources describe it as a vehicle launched by the Altman brothers in 2020, with a broad mandate rather than a psychedelic-specific strategy. Its relevance to psychedelic medicine comes from Journey Colab, where Apollo Projects appears in launch and Series A financing evidence. The record should be treated as moderate-confidence broad venture capital with a verified Journey Colab connection.

The Arizona Biomedical Research Commission (ABRC) is a state government body within the Arizona Department of Health Services that funds biomedical research, having become the first state agency in the US to direct $5 million toward randomized controlled clinical trials of psilocybin whole mushrooms for conditions including PTSD, depression, and addiction. The ABRC oversees the Arizona Psilocybin Research Advisory Council and has since expanded its psychedelic research portfolio to include an additional $5 million for ibogaine clinical trials.

ARK Invest, legally ARK Investment Management LLC, is an active investment manager founded by Cathie Wood in 2014. It is based in New York, United States, and focuses on disruptive innovation across public markets, with some private-market exposure through ARK Venture Fund. ARK has published dedicated research on psychedelic therapeutics and the field’s clinical and commercial potential. Its public research and thematic investment approach make it a relevant institutional stakeholder for psychedelic drug development companies, especially those advancing novel therapies into clinical and public-market stages.

AtaiBeckley Inc. is a clinical-stage biotechnology company formed in 2025 through the strategic combination of atai Life Sciences and Beckley Psytech. It operates as a public company focused on developing rapid-acting, durable, and convenient mental health treatments, with a strong psychedelic-therapeutics emphasis. Its principal executive office is in New York, New York, United States. AtaiBeckley matters in the psychedelic ecosystem because it combines clinical development capabilities with a public-market platform that can support late-stage psychedelic drug programs. Public disclosures describe pipeline work that includes BPL-003 and note that the company’s psychedelic-based therapies are being advanced through the Beckley Psytech strategic investment and later combination.

BTIG is a global financial services firm that provides institutional sales and trading, research, and investment banking services. Its website describes the firm as serving institutional and corporate clients across public markets, with a strong healthcare banking presence. The firm’s New York office at 65 East 55th Street is the address most prominently listed on BTIG’s site. In the psychedelic ecosystem, BTIG is relevant primarily as a healthcare and capital markets intermediary rather than a dedicated psychedelic investor. BTIG’s healthcare investment banking coverage includes biotechnology and pharmaceuticals, which can overlap with psychedelic drug-development companies if they seek public-market financing, strategic advice, or aftermarket support.

BVF Partners L.P. is a private investment manager based in San Francisco, California. Public filings and market data describe it as an SEC-registered investment adviser and biotechnology-focused investor, rather than a broad consumer or software venture fund. In the psychedelic ecosystem, BVF Partners matters mainly as a healthcare and drug-development capital provider whose investment style aligns more with life sciences than with lifestyle psychedelics. Publicly available sources point to biotech as its core theme, which makes it potentially relevant to companies developing regulated therapeutic compounds and clinical-stage programs.

The Beckley Foundation is a UK-based non-profit founded in 1998 and based in Oxford, with a global remit focused on psychedelic research and drug policy reform. It works through scientific and policy programmes and collaborates with researchers, political leaders, and institutions internationally. Its website describes its purpose as investigating psychoactive substances and developing evidence-based drug policies grounded in health, harm reduction, cost-effectiveness, and human rights. In psychedelic medicine and drug policy, the Beckley Foundation functions as a research and reform organization rather than a patient service group. Current documented work includes the Beckley/Imperial research programme, new collaboration with King’s College London on LSD and mystical experience research, and policy outputs such as Roadmaps to Regulation: MDMA, which argues for decriminalization and a strictly regulated legal market. This makes it relevant for researchers, clinicians, funders, and policy groups interested in clinical evidence, regulatory models, and translating psychedelic science into access and reform discussions.

Fundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.

Beijing Medical Award Foundation (北京医学奖励基金会) is a Beijing-based public charity established in 2002 in Xicheng District, dedicated to enhancing medical standards through professional incentives, grants, and awards recognising biomedical research achievement. The foundation provides funding and recognition supporting clinical and scientific excellence in Chinese medicine, including psychiatry and neuroscience fields.

Berenberg, legally Berenberg, Gossler & Co., is a long-established private bank and financial services group founded in 1590 in Hamburg. It operates across investment banking, asset management, corporate banking, and wealth management, and describes itself as one of Europe’s leading private banks. In the psychedelic ecosystem, Berenberg matters mainly as a public-markets and healthcare-capital-markets participant rather than a dedicated psychedelic specialist. Its published equity and healthcare strategies focus on growth-oriented companies, and its investment banking business has supported multiple life sciences and biotech financings, including healthcare-sector equity transactions.

Bicycle Day Ventures is a psychedelic-focused angel syndicate associated with Chris Kantrowitz. AngelList materials describe a syndicate thesis around psychedelic medicine and related industries, with visible portfolio exposure to companies including Beckley Psytech and Quantified Citizen. The syndicate remains a useful early-stage investor record because it is explicitly focused on psychedelic medicine, but its public identity fields are lighter than those of institutional funds. Public copy should stay precise about the syndicate structure and avoid overstating firm scale or office details.

BlackRock is a global asset manager and fiduciary investor founded in 1988 in New York. Its investment stewardship business engages with public companies and votes on behalf of clients across index and active portfolios. Public BlackRock location pages list its New York office at 50 Hudson Yards, New York, NY 10001, United States. In the psychedelic ecosystem, BlackRock is relevant primarily as a large public-markets stakeholder rather than a dedicated psychedelic specialist. Its stewardship and portfolio activities span global public companies and multiple asset classes, so it may appear as a shareholder in listed life sciences or healthcare names even though it does not advertise a public psychedelic focus.

Blackhawk Growth Corp. is a publicly traded Canadian investment holding company / investment issuer that invests in equity and debt instruments of companies to generate shareholder returns. Public filings and exchange listings place the company in Vancouver, British Columbia, Canada, while the company itself has also described its strategy as active support for portfolio companies in North America. It matters in the psychedelic ecosystem because Blackhawk has publicly backed psychedelic-related drug development, including MindBio Therapeutics, which it described as a clinical-stage company pioneering psychedelic microdosing research. That makes Blackhawk a relevant crossover investor in the adjacent cannabis, mental health, and psychedelic therapeutics landscape rather than a pure-play life sciences fund.

Entrepreneur and donor listed in psychedelic philanthropy ecosystems with public wellbeing-focused giving activity.

Boxer Capital is a biotechnology investment firm and private investment fund based in San Diego, California. Its public materials describe it as a full life cycle investor focused on fundamental, research-based investing across private and public markets, with activity spanning early-stage through late-stage biotech. It matters to the psychedelic ecosystem because its investing style overlaps with the kinds of capital needed by drug-development companies, including crossover, private, and public-market financing. Boxer Capital’s public disclosures emphasize investing across the drug development lifecycle and supporting therapeutics companies from company formation through late-stage development, which can make it relevant to psychedelic medicine companies even when they are not explicitly psychedelic-focused.

The Brain & Behavior Research Foundation (formerly NARSAD) is the world's largest private funder of psychiatric research, having awarded over $475 million to more than 5,000 scientists—including grants specifically supporting psilocybin-assisted therapy trials, ketamine research, and other innovative treatments for depression, PTSD, and schizophrenia. In 2023 alone, the foundation funded seven grants advancing psilocybin-based research and has supported over 90 ketamine-related projects, making it a cornerstone funder of emerging psychedelic science.

Canada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.

The Bronx Veterans Medical Research Foundation (BVMRF) is a 501(c)(3) nonprofit that administers extramural research funding for the James J. Peters VA Medical Center and VA Hudson Valley Health Care System, supporting mental health, biomedical, and rehabilitation research focused on veteran populations. In the psychedelic context, it provides the administrative research infrastructure supporting MDMA-assisted therapy for PTSD and ketamine studies conducted at the Bronx VA's Center for Psychedelic Psychotherapy and Trauma Research.

The Burroughs Wellcome Fund (BWF) is an American biomedical research foundation headquartered in Research Triangle Park, North Carolina, that grants over $40 million annually to support early-career scientists and fields poised for significant advancement but currently undervalued—a mandate that encompasses avant-garde psychiatric pharmacology. The Fund traces its origins to Burroughs Wellcome Co., the US pharmaceutical subsidiary whose pioneering monoaminergic pharmacology research laid groundwork foundational to today’s psychedelic medicine field.

Canaccord Genuity Group Inc. is a global independent investment dealer with capital markets and wealth management operations, including investment banking and advisory services for public and private companies. Public company filings identify its head office in Vancouver, British Columbia, Canada. In the psychedelic ecosystem, Canaccord Genuity is relevant mainly as a capital-markets adviser rather than a dedicated psychedelic specialist. Its published transactions show activity in adjacent areas such as cannabis, healthcare, and public growth financings, which can intersect with psychedelic companies that access public markets or pursue strategic capital raises.

Canadian federal health research funder with direct psilocybin psychotherapy trial grants.

Canada�s federal health research funding agency setting national biomedical and health-services research priorities.

Cantor Fitzgerald is a global financial services firm founded in 1945 that provides investment banking, capital markets, fixed income, equities, prime services, research, asset management, and related services. Its website identifies it as a privately owned firm with a broad institutional and public-markets orientation, and its headquarters is in New York, New York, United States. For the psychedelic ecosystem, Cantor Fitzgerald appears relevant mainly as a capital-markets and financing intermediary rather than a dedicated psychedelic investor. Public materials show activity in investment banking, SPACs, PIPE placements, and asset management, which can make it relevant to public psychedelic companies seeking listings, financings, or coverage, but there is no public evidence of a specific psychedelic focus.

Psychedelic ecosystem founder and donor/investor associated with mission-aligned philanthropic support activity.

The Carey and Claudia Turnbull Family Foundation is a private philanthropic foundation that has been one of the earliest and most influential funders of psychedelic medicine research, supporting psilocybin studies at NYU, Yale, and Johns Hopkins—including helping establish Yale’s psychedelic psychiatry training curriculum and endowing research at the NYU Center for Psychedelic Medicine, where Carey Turnbull chairs the advisory board. Carey Turnbull also serves as President of the Heffter Research Institute and co-founded B.More and Ceruvia Lifesciences, further extending the family’s commitment to advancing psychedelic therapies for depression, addiction, and OCD.

Catalio Capital Management is a New York-based healthcare investment firm that invests across private, public, and credit markets. Its public materials emphasize innovative healthcare companies across the company lifecycle, with a strong orientation toward biomedical technology. Catalio belongs in the psychedelic ecosystem as a healthcare-specialist investor with atai-related investments and a historical COMPASS Pathways connection through Camden Partners Nexus. It should be read as a life-science investor with repeated source-backed sector exposure, not as a dedicated psychedelic fund.

The Chief Scientist Office (CSO) of the Scottish Government funds NHS and health research across Scotland, and has supported University of Edinburgh evaluability work on ketamine-assisted therapy and the development of the Scottish Psychedelic Research Group to build Scotland’s capacity for psychedelic-assisted therapy studies.

Individual philanthropic donor listed in ecosystem mappings with limited publicly structured recipient-level disclosures.

U.S. federally directed defense-health research program office administering targeted grants, including mental-health priorities.

Brazil's National Council for Scientific and Technological Development (CNPq) is the country's primary public funding agency for scientific research, providing grants, scholarships, and R&D support to universities and research institutions nationwide. CNPq ranks among the top global funders of psychedelic science, having supported seminal ayahuasca clinical trials, pharmacological studies, and productivity fellowships for researchers who established Brazil as a world leader in psychedelic psychiatry.

CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is Brazil's federal agency for graduate education improvement, providing scholarships, postdoctoral fellowships, and institutional research grants to universities nationwide. Ranked among the top-six global funders of psychedelic research in a 2023 Scopus analysis, CAPES has financed ayahuasca neuroscience studies, clinical investigations, and postdoctoral programmes that underpin Brazil's internationally recognised psychedelic research ecosystem.

The Council on Spiritual Practices (CSP) is a US non-profit organisation founded in 1993 by Robert Jesse to support research and education on the safe and effective use of entheogens and primary religious experience. CSP was instrumental in initiating the landmark Johns Hopkins psilocybin research programme with Roland Griffiths, co-funding pivotal early studies on psilocybin's mystical-experience effects that re-established psychedelic science and shaped clinical frameworks globally.

The Council on Spiritual Practices Fund at the San Francisco Foundation is a named charitable fund administered through the San Francisco Foundation, a regional community foundation serving the Bay Area. It channels philanthropic resources in support of research and education on entheogenic substances and primary religious experience, extending the grant-making mission of the Council on Spiritual Practices through a community foundation structure.

Cowen is a U.S.-based diversified financial services firm and institutional investor platform that has historically combined investment banking, research, sales and trading, prime brokerage, and investment management. Public filings describe Cowen as founded in 1918 and headquartered in New York, with principal executive offices at 599 Lexington Avenue in New York City. In the psychedelic ecosystem, Cowen matters mainly as a broad healthcare capital provider rather than a dedicated psychedelic investor. Its public investment management strategies have included healthcare royalties, private healthcare investing, and public and private healthcare strategies, which can place it near adjacent biotech and neuroscience opportunities even though no public psychedelic focus is stated.

The Czech Health Research Council (AZV ČR) is an organisational component of the Czech Ministry of Health responsible for funding applied health research, distributing over 1 billion CZK annually across approximately 90 supported projects per year. It provided the primary grant for the PSIKET001 trial — a landmark double-blind comparison of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — with a total budget of 12 million CZK.

Executive and donor with publicly documented support for psychedelic policy and research-aligned initiatives.

Deerfield Management Company is a healthcare investment firm launched in 1994. Its public materials describe it as an investor across therapeutics, medical devices, diagnostics, digital health, and healthcare services, investing across the capital structure and at all stages of company development. Deerfield’s contact page lists its New York City office at 345 Park Avenue South in New York, New York, United States. Deerfield is relevant to the psychedelic ecosystem primarily through its broad therapeutics focus and its ability to back early-stage to later-stage life science companies. While its public website does not identify a dedicated psychedelic program, its investment platform includes drug-development-oriented work and a portfolio spanning early-stage therapeutics, which makes it a plausible investor in adjacent mental-health and neurotherapeutics opportunities.

US defense research funder with psychedelic-informed neuropsychiatric R&D (Focused Pharma).

Mission-driven company with publicly documented donations and advocacy support for psychedelic research and policy reform initiatives.

EF Hutton is a global full-service investment bank focused on middle-market and emerging growth companies, with public and private offerings across debt and equity capital markets. Its website lists product offerings including investment banking and advisory, private credit, asset-backed finance, credit tenant lease and ground lease finance, private equity, and project and infrastructure finance. Public materials describe the firm as headquartered in New York, New York. In the psychedelic ecosystem, EF Hutton is relevant primarily as a capital markets and research intermediary rather than as a dedicated psychedelic specialist. Public materials show the firm has provided sell-side research on small and mid-cap companies and has covered or advised companies in the broader mental health and biotech space, which can overlap with public psychedelic issuers, but its public positioning remains industry-agnostic rather than explicitly psychedelic-focused.

Empath Ventures is a venture capital firm focused on psychedelic medicine and related therapeutic approaches. Public profiles place the firm in Los Angeles, California, United States, and describe it as an early-stage investor with activity across seed and Series A stages, with some sources also indicating broader stage coverage. The firm is relevant to the psychedelic ecosystem because it has publicly positioned itself around psychedelic medicine companies and adjacent health technologies. Public references also connect Empath Ventures to companies and themes in psychedelic medicine, neurotechnology, and novel therapeutics.

Empower Psychedelics is a Canada-based non-profit conducting Health Canada-approved psychedelic-assisted group therapy research for first responders and military veterans in partnership with MAPS Canada. Founded in 2020 by former first responders, the organization received a $205K Mitacs grant with the University of Quebec in Montreal for a two-year clinical research program.

Empower Research Inc. is the corporate research entity behind Empower Psychedelics, running Health Canada-approved trials on psychedelic-assisted group therapy for first responders in partnership with MAPS Canada. The organization has also studied medically perceived benefits of psychedelics and cannabinoids among first responders and military personnel.

The Etheridge Foundation is a 501(c)(3) non-profit founded by Grammy and Academy Award-winning musician Melissa Etheridge following the 2020 opioid overdose death of her son Beckett, funding scientific research into plant-medicine treatments for opioid use disorder and related mental health conditions. The Foundation has co-funded Usona Institute's 5-MeO-DMT research program and raised over $1 million at its inaugural Rock Jam gala for psychedelic medicine development.

EU supranational research funding framework supporting psilocybin clinical research (PsyPal).

Funds frontier research across all fields of science and scholarship in Europe. ERC Starting / Consolidator / Advanced Grants have supported multiple psychedelic neuroscience projects.

Evercore is a publicly traded global independent investment banking advisory firm, not a venture fund or direct psychedelic investor. It was founded in 1995 and is headquartered in New York, United States, with offices and affiliate offices across major financial centers in North America, Europe, the Middle East, and Asia. In the psychedelic ecosystem, Evercore’s relevance is mainly as a capital markets and strategic advisory firm rather than a specialist life-sciences investor. Its healthcare and biotech coverage, private capital markets, and public-company advisory work can make it relevant to psychedelic companies seeking M&A advice, financing, or public-market transactions.

Philanthropic foundation connected to Evolve Ventures focused on funding mental-health and psychedelic research initiatives.

Evolve Ventures is the venture arm of EVOLVE, an umbrella organization that says it has two divisions: Evolve Ventures and Evolve Foundation. The firm says Evolve Ventures was initially funded by the Shao family with a $100 million pool and invests in for-profit companies aligned with its mission. The organization describes its work as global, with a particular focus on the United States and China. Evolve Ventures appears in the psychedelic ecosystem through its investments in companies such as Beckley Waves, Homecoming, and MycoMedica on its public investments page. Its portfolio also includes mental health, meditation, and consciousness-oriented companies, which places it near the broader psychedelic-adjacent landscape even when the company itself is not a direct drug-developer.

Ferring Ventures is an investment vehicle associated with Ferring's broader life-science and biopharmaceutical platform in Switzerland. Public and registry materials tie the entity to St-Prex and place it within a larger organization focused on therapeutic innovation and commercialization. Ferring Ventures matters for psychedelic coverage because it shows strategic corporate capital entering the space through atai-linked financings in 2025. That makes it more relevant than a passive one-off holder, while still leaving it outside the category of dedicated psychedelic investors.

The Fetzer Institute is a private non-profit foundation based in Kalamazoo, Michigan with $830M in assets, dedicated to building the spiritual foundation for a loving world through research at the intersection of science, spirituality, and consciousness. With annual grants exceeding $12M, the Institute supports interdisciplinary work in consciousness studies and contemplative practice that intersects with the emerging field of psychedelic medicine.

The Foundation of Hope for Research and Treatment of Mental Illness is a North Carolina non-profit that partners with UNC Chapel Hill's Department of Psychiatry to fund cutting-edge psychiatric research, with a mission to conquer mental illness through scientific investment. The Foundation's seed grants support a portfolio of mental health research at UNC Chapel Hill that includes ketamine and emerging psychedelic-assisted therapy studies alongside broader mental health initiatives.

Founders Fund is a generalist venture capital firm known for backing large, category-defining technology companies across sectors. Its public positioning is broad rather than healthcare-specific, and the firm is not publicly organized around psychedelic medicine. Its relevance to psychedelic medicine comes from participation in COMPASS Pathways' 2020 Series B round. That makes Founders Fund a meaningful crossover investor in a landmark psilocybin drug developer, but not a dedicated psychedelic investor.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is a New York-based non-profit founded in 2000 by actor Michael J. Fox that has raised over $2 billion for Parkinson's disease research and treatments. MJFF has funded pioneering psychedelic research including the first psilocybin trial in a neurodegenerative disease (UCSF/Yale, for Parkinson's-related depression) and a ketamine infusion trial at Yale for treatment-resistant depression in Parkinson's patients.

Future Ventures is a venture capital firm co-founded by Steve Jurvetson and Maryanna Saenko. The firm says it focuses on seed and early-stage investments in founder-led, mission-driven companies and describes itself as based in Pacifica, California through Saenko’s public bio and the firm’s Bay Area footprint. Future Ventures matters in the psychedelic ecosystem because it has backed and publicly listed atai Life Sciences and Osmind, both adjacent to mental health and psychedelic medicine infrastructure. Its public materials also emphasize biology, therapeutics, and frontier technology, which aligns with the broader ecosystem around drug development and digital care platforms.

Grantmaking and philanthropic platform supporting nonprofits in consciousness, wellbeing, and psychedelic-adjacent ecosystems.

Gaingels is a venture investment syndicate and network that co-invests with venture capital leads across a wide range of sectors and stages, from pre-seed to pre-IPO. Its public materials describe it as an LGBTQIA+/allies investor network focused on diversity, inclusion, and access in venture. The organization’s mailing address is in New York, New York, United States. Gaingels says it invests globally and supports venture-backed companies in any sector, with a notable emphasis on healthcare and biotech alongside other high-growth categories. In the psychedelic ecosystem, that makes it relevant as a potential co-investor for drug-development companies that fit its broader mental health and biotech orientation, even though its public portfolio page does not single out psychedelics as a dedicated focus.

Gateway for Cancer Research is a US non-profit that funds innovative cancer research including exploration of psychedelic-assisted therapies for cancer-related psychological distress and end-of-life care. The organization has actively promoted and publicized expert calls for expanded study of psilocybin and other psychedelics to address the anxiety, depression, and existential distress experienced by cancer patients.

The George Sarlo Foundation is the philanthropic vehicle of Holocaust survivor and Silicon Valley venture capitalist George Sarlo, who credits guided psychedelic experiences with resolving his childhood trauma and became one of the earliest major private donors to psychedelic science. The Foundation has contributed nearly $2 million to psychedelic research, including a $1 million pledge to MAPS for MDMA-assisted therapy development and grants to CIIS for psychedelic therapist diversity training.

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

The Antonio J. Gracias Family Foundation is a Chicago-based private philanthropic foundation established in 2021 that awarded a $16 million gift to Harvard University to fund interdisciplinary psychedelic research, including the Project on Psychedelics Law and Regulation (POPLAR) at Harvard Law School and the Transcendence and Transformation Initiative at the Center for the Study of World Religions. With $94.6 million in assets, the foundation identifies psychedelics as a priority research area alongside quantum science and cardiovascular medicine.

H.C. Wainwright & Co., LLC is a New York-based full-service investment bank offering investment banking, equity research, sales and trading, strategic advisory, and corporate access services. The firm says it serves public and private growth companies across multiple sectors and regions, and its office is at 430 Park Avenue, New York, New York 10022. In the psychedelic ecosystem, H.C. Wainwright matters primarily as a capital-markets and conference platform rather than as a dedicated psychedelic specialist. Its public materials show a strong life sciences and biotechnology orientation, and its events have included companies such as Awakn Life Sciences and Cybin in the broader psychedelics space.

The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.

Healing Hearts, Changing Minds, Inc. (HHCM) is a Massachusetts-based nonprofit grant foundation committed to trust-based philanthropy in psychedelic-assisted therapy, founded by Robert Ansin following a transformative personal psilocybin experience. The foundation has awarded over $566,000 in grants under its 'Walking Each Other Home' fund to support psilocybin and ketamine-assisted therapy in end-of-life care, including funding for war-affected Ukrainian veterans.

The Health Research Board (HRB) is Ireland's primary statutory health research funding agency, which has awarded grants to Trinity College Dublin's Psychedelic Research Group to investigate psychedelics' immune effects in depression and the feasibility of psilocybin for cocaine-use disorder. The HRB also funds the KARMA-DEP(2) ketamine trial for treatment-resistant depression at St Patrick's University Hospital in Dublin, making it a key enabler of Ireland's emerging psychedelic medicine ecosystem.

Non-profit organization funding and coordinating research on classic psychedelics and related therapies.

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.

Hercules Capital, Inc. is a publicly traded specialty finance company and business development company focused on senior secured venture growth loans for venture capital-backed companies. It was founded in 2003 and is based in San Mateo, California, in the United States. Hercules is relevant to the psychedelic ecosystem because its life sciences practice finances biotechnology and other healthcare companies at clinical and commercial stages, including companies in the broader CNS and drug development space. Public filings show Hercules has been a lender to ATAI Life Sciences, making it a financing counterpart to a psychedelics-focused public company.

Platform organization developing and supporting psychedelic and mental-health initiatives with philanthropic backing.

French National Institute of Health and Medical Research (INSERM), a national public biomedical research organization with active discourse and research engagement on psychedelic medicine.

Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.

Instituto de Salud Carlos III (ISCIII) is Spain's national public health research agency, managing the CIBERSAM network (Centro de Investigación Biomédica en Red de Salud Mental) which co-funds biomedical mental health research across Spanish universities and hospitals. Through CIBERSAM, ISCIII has co-funded preclinical and translational research on psilocybin as an antidepressant and supports researchers contributing to the European psychedelic therapy landscape.

ICEERS (International Center for Ethnobotanical Education, Research and Service) is a nonprofit supporting ethnobotanical research, policy engagement, and community-informed programming around ayahuasca, iboga, and related plant medicines.

Iter Investments is a venture capital firm focused on emerging companies developing alternative therapeutics for behavioral and mental health, with a stated emphasis on the psychedelic ecosystem. The firm’s public materials describe it as a Florida-based investor, with headquarters in South Florida. Iter matters in the psychedelic ecosystem because it backs companies across the sector’s value chain, including drug development, clinics, digital platforms, and supporting infrastructure. Its public portfolio includes Psygen, Awakn Life Sciences, Wesana, PsyTech, and Nucleus-related ecosystem assets, showing a broad strategy beyond a single therapeutic modality.

JLS Fund is a venture capital fund focused on neuroscience and psychedelic medicine. Its website says the firm was founded in 2019 and lists a New York office at 40 Sutton Place, New York, USA. The fund is active across the psychedelic ecosystem through investments and advisories in companies such as Enthea, Psilera, TRIPP, Gilgamesh, and ProNovo Therapeutics. It also publishes regular industry commentary on psychedelics and neuroscience, which helps position it as a visible specialist investor in the sector.

The James S. McDonnell Foundation is a private philanthropic organization based in St. Louis, Missouri, supporting research in cognitive and behavioral sciences, complex systems science, and 21st-century science education. The foundation has funded clinical research on cognitive recovery following electroconvulsive therapy and general anesthesia.

Jefferies is a global full-service investment banking and capital markets firm, rather than a specialist psychedelic investor. Its public materials describe the firm as operating worldwide, with principal offices in New York and regional headquarters in London and Hong Kong. In the psychedelic ecosystem, Jefferies matters mainly as a broad capital-markets and research platform that has published industry thought leadership on psychedelics and mental health. Its public primer on mental health and psychedelics notes active investor interest in the space and discusses public and private psychedelic drug-development companies, but it does not establish Jefferies as a dedicated psychedelic-focused fund.

Johnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States. In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.

Reciprocity trust linked to Journey Colab focused on equitable benefit sharing and funding commitments around psychedelic medicine development.

Entrepreneur included in psychedelic philanthropy ecosystem lists; available public disclosures are currently limited.

The Juvenile Bipolar Research Foundation is a US non-profit dedicated to funding scientific research into bipolar disorder in children and adolescents. The foundation has supported clinical research on intranasal ketamine for pediatric bipolar disorder and neurobiological studies of ketamine's effects in children and adults with bipolar disorder.

Kevin O'Leary is a Canadian entrepreneur and investor best known for his television role on Shark Tank and for building an investor brand around startups and private-market deals. His official site presents him as actively looking for new business proposals, and third-party profiles place him in Toronto, Ontario, Canada, while his public investor activity is global. In the psychedelic ecosystem, O'Leary is notable as an early investor and public advocate for MindMed, a psychedelic-focused drug-development company. Public interviews describe his interest as centered on regulated pharmaceutical development and binary, long-duration biotech-style outcomes rather than recreational use.

Leafy Tunnel is a venture capital firm focused on alternative medicine, with an emphasis on medicinal cannabis and psychedelics. Its public-facing materials describe it as an early-stage investor and place its headquarters in London, United Kingdom. In the psychedelic ecosystem, Leafy Tunnel matters because it has publicly positioned itself around medical cannabis and global medical psychedelics opportunities, with a stated focus on Seed and Series A investing. Public funding coverage shows it led Lyphe Group’s £5m Series A round in 2022, supporting expansion across Europe.

Levitee Labs Inc. is a British Columbia company that was incorporated on January 23, 2019 and later became listed on the Canadian Securities Exchange under the symbol LVT. Public filings describe it as an integrative wellness company with activities aimed at alternative medicine and the broader psychedelic industry. The company’s public disclosures frame its role around acquiring and building wellness assets complementary to the evolving psychedelic sector, including clinics, pharmacies, nutraceuticals, and other adjacent healthcare businesses. That makes Levitee Labs relevant as an operator and capital allocator around psychedelic-adjacent healthcare infrastructure rather than a traditional early-stage venture fund.

MBX Capital is an early-stage venture capital firm focused on deep health companies, with an official FAQ stating it is agnostic to sector so long as the company has a clear deep health vision. The firm says it typically invests in companies’ first or second institutional rounds and can also participate in later-stage financings. Its public mailing address is in Claymont, Delaware, United States. In the psychedelic ecosystem, MBX Capital is relevant because its portfolio page includes Journey Colab, described as building psychedelic therapies for addiction, alongside other mental-health and neuro-related companies. That makes MBX Capital a broader deep-health investor with at least one public psychedelic-adjacent portfolio company and a stated willingness to invest globally when the opportunity fits.

Matt Mullenweg is the co-founder and CEO of Automattic, the company behind WordPress.com, WooCommerce, Jetpack, and Tumblr, and he also describes Audrey Capital as an angel investment and research company. Public sources characterize him as an angel investor with a strong preference for open-source-oriented companies and early-stage startups. His relevance to the psychedelic ecosystem is indirect rather than thematic: available public materials do not show a specific psychedelic investment thesis or public psychedelic portfolio. He is still a useful investor to track in adjacent infrastructure and software circles because his investment activity is centered on early-stage, open-source-friendly businesses, not life sciences or psychedelic drug development.

Maxim Group LLC is a New York-based full-service investment bank, securities firm, and wealth management platform that provides investment banking, capital markets, research, sales and trading, and private wealth services. Public sources list its headquarters in New York, NY, with offices in Florida, New Jersey, and Connecticut. In the psychedelic ecosystem, Maxim Group matters primarily as a Wall Street coverage and capital-markets participant rather than as a dedicated psychedelic investor. Its research platform has covered multiple psychedelic-focused public companies, and its investment-banking business also works across healthcare and biotechnology, which places it near the financing activity around the sector.

The Medical Research Council (MRC) is a UK government body under UKRI that funds biomedical and clinical research across all aspects of human health. In the psychedelic field, the MRC co-funded the KARE trial — the UK's largest study of ketamine-assisted therapy for alcohol use disorder, led by the University of Exeter — and has supported additional ketamine cognition research.

Australian Government medical research funder with explicit psychedelic trial grants (including ketamine, psilocybin, and MDMA).

Mike Novogratz is an American investor and the founder and CEO of Galaxy, where he leads a global digital-assets and blockchain-focused investment platform. Public company filings list his principal business address in New York City, and Galaxy’s headquarters is also reported as New York City. He matters to the psychedelic ecosystem mainly as a public backer of psychedelic biopharma through atai Life Sciences, where investor lists and commentary name him among notable investors. Public references also link Novogratz to the broader psychedelic investment network alongside other prominent financiers involved in drug-development and mental-health innovation.

Mission Club is an angel investor community and education platform. Public materials describe it as supporting the psychedelic ecosystem and related startups, with a focus on early-stage investing. The organization appears to be based in Toronto, Canada, based on a public event listing and a Canadian corporate registration record for a Mission Club entity. It has public ties to psychedelic community-building and investor programming rather than a large institutional fund structure.

Mitacs is a Canadian nonprofit research organization founded in 1999 that fosters collaboration between academia, industry, and government through internship, fellowship, and innovation programs jointly funded by federal and provincial partners. In the psychedelic field, Mitacs provided an Accelerate grant (IT32313) to Empower Psychedelics for a Health Canada-approved clinical trial examining psilocybin-assisted group therapy for first responders and veterans in partnership with MAPS Canada.

Morgan Stanley is a global financial services firm and institutional investor founded in 1935. Public Morgan Stanley pages describe the firm as headquartered in New York, with worldwide offices and clients across institutions, corporations, governments, and individuals. In the psychedelic ecosystem, Morgan Stanley’s relevance is mostly indirect: its investment management arm covers global public and private markets, and its published research has discussed psychedelics as an emerging theme in healthcare and investing. The firm does not present a public psychedelic investment focus, but its broad capital-markets and growth-investing platform could make it relevant to late-stage life sciences and adjacent healthcare companies.

The National Alliance for Research on Schizophrenia and Depression (NARSAD), now the Brain & Behavior Research Foundation (BBRF), is the United States’ largest non-governmental funder of mental health research, having awarded over $430 million across 6,200+ grants to more than 5,100 scientists worldwide since 1987. NARSAD-funded Distinguished Investigator grants supported early research into ketamine’s antidepressant mechanism at Columbia University, as well as studies of salvinorin A pharmacology and ketamine augmentation of electroconvulsive therapy for depression.

NIH institute funding psychedelic oncology-adjacent mental health research, including psilocybin therapy studies for advanced cancer-related distress.

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

NIH center that accelerates the translation of biomedical discoveries into health solutions. NCATS' Clinical and Translational Science Awards (CTSA) program funds the infrastructure at academic medical centers that supports emerging research including psychedelic-assisted therapy trials.

NIH institute funding psychedelic clinical research, including psilocybin-assisted psychotherapy protocols in depression and chronic pain populations.

U.S. federal institute focused on complementary/integrative research and evidence programs including psychedelic-adjacent contexts.

The National Center for Research Resources (NCRR) was a National Institutes of Health centre that funded biomedical research infrastructure, clinical and translational science programmes, and shared research resources until its dissolution in 2011, when its programmes were reorganised primarily into the new National Center for Advancing Translational Sciences (NCATS). NCRR infrastructure and clinical research awards supported early NIH-funded investigations into glutamate-modulating medications for major depressive disorder that laid the mechanistic groundwork for understanding ketamine’s rapid antidepressant effects.

The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.

The National Health and Medical Research Council is the Australian Government body for health and medical research funding, evidence guidance, and research ethics. It is tracked here as a public funder for Australian clinical research.

UK public health research funder and implementation infrastructure supporting NHS-oriented evidence generation.

UK public health research funder with NIHR-backed psilocybin addiction trial funding.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

NIH institute funding neuroscience projects involving psychedelics, including psilocybin-related chronic pain and neuroplasticity investigations.

NIH institute with co-funded psychedelic research activity, including projects on psychedelics for older adults with chronic pain.

NIH institute funding psychedelic-related alcohol use disorder research, including psilocybin-assisted treatment and derivative development projects.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a US National Institutes of Health institute dedicated to research on alcohol use disorder and its public health impacts, supporting approximately $500 million in research annually. NIAAA has funded studies exploring both ketamine administration for acute alcohol use disorder in the emergency department and psilocybin-assisted therapy to understand the neurobehavioral mechanisms underlying alcohol use disorder treatment.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.

Negev Capital is a venture capital fund focused on CNS and brain-health therapeutics, with a stated strategy centered on seed to Series A investments. The fund says it is domiciled in the Cayman Islands and that key team members are based in Limassol, Cyprus, Vienna, and New York. It matters in the psychedelic ecosystem because Negev Capital has backed and exited multiple companies in psychedelic-derived and neuropsychiatric drug development, including Gilgamesh Pharmaceuticals, Mindset Pharma, Bright Minds Biosciences, and others. The fund describes its thesis as supporting psychedelic-derived and novel neuropsychiatric compounds that can mature into mainstream therapeutic categories.

Neo Kuma Ventures LLP is a London-based venture capital investor focused on psychedelic healthcare and adjacent drug-development opportunities. Public materials describe it as investing in early-stage psychedelic healthcare companies, with a global market scope and a European tilt. The firm is relevant to the psychedelic ecosystem because it has backed several of the sector’s best-known companies and positions itself around clinical research, therapeutics, and regulated healthcare delivery. Public profiles and coverage identify portfolio exposure to companies such as Atai Life Sciences, Beckley Psytech, and Bright Minds Biosciences.

Private foundation with explicit support for psychedelic research, science communication, and ecosystem development.

Noetic Fund is a Toronto-based venture firm investing in early-stage technologies focused on mental health and wellbeing. Its public materials describe a diversified strategy across novel drug therapeutics, psychedelic-assisted therapies, digital health, medical devices, wearables, and other evidence-backed solutions, with a global outlook and emphasis on early intervention and prevention. The firm is explicitly tied to the psychedelic medicine ecosystem through its own fund announcements, reading list, and portfolio disclosures. Publicly named investments include CaaMTech, the Alexander Shulgin Research Institute, and Damona Pharmaceuticals, which positions Noetic as an active capital provider in psychedelic drug development and adjacent mental health innovation.

Philanthropic initiative focused on funding and scaling mental-health innovation, including psychedelic-related ecosystem efforts.

The Novo Nordisk Foundation is a Danish enterprise foundation that funds scientific, health, and societal research. In this dataset it is tracked as a funding stakeholder for clinical research rather than as a trial sponsor operating company.

OMX Ventures is a venture capital firm based in Chicago, Illinois, focused on bioengineering and life sciences investing. Its public materials describe a technology-first approach centered on early-stage companies working across biology, big data, AI, therapeutics, bio tools, diagnostics, and synthetic biology. In the psychedelic ecosystem, OMX matters because it is a founding investor in Delix Therapeutics, a company developing non-hallucinogenic versions of psychedelic compounds for psychiatric and neurological indications. OMX has also publicly participated in other drug-development and biotech rounds, suggesting a broader interest in therapeutics that overlap with psychedelic-adjacent neuroscience.

Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.

Oppenheimer & Co. Inc. is a global financial institution offering wealth management, capital markets, and investment banking services. Its institutional-facing businesses include equity research, investment banking, and institutional services, and its principal place of business is in New York, New York. In the psychedelic ecosystem, Oppenheimer matters primarily as a generalist capital-markets and healthcare finance platform rather than a specialist psychedelic investor. Its healthcare research and investment banking coverage spans biotechnology, biopharmaceuticals, specialty pharmaceuticals, and emerging-growth companies, which can make it relevant to public and private life-sciences issuers that overlap with psychedelic drug development.

The Oppenheimer Family Psychosocial Oncology and Palliative Care Research Grants is a philanthropic grant fund supporting research at Dana-Farber Cancer Institute's Department of Psychosocial Oncology and Palliative Care, including Dr. Yvan Beaussant's psilocybin-assisted therapy studies for demoralization and existential distress in hospice patients. The program co-funds trials alongside the Heffter Research Institute, Usona Institute, and Nikean Foundation.

OrbiMed Advisors is a global healthcare investment manager that invests across the life sciences and healthcare sectors, from seed-stage private companies to large publicly traded companies. Its platform spans public equity, private equity, and private credit/royalty strategies, and the firm says its investment business was founded in New York City in 1989. For the psychedelic ecosystem, OrbiMed matters mainly as a large, healthcare-focused capital provider rather than as a specialist psychedelic backer. Its public materials describe broad investing across biopharmaceuticals, medical devices, diagnostics, and healthcare services, with capital deployed across the full company lifecycle and capital structure, which makes it relevant to psychedelic companies only where they fit broader drug development or healthcare themes.

Origin Therapeutics Holdings Inc. is a publicly listed, actively managed investment issuer focused on equity investments in psychedelics-related companies. Public company materials place it in Vancouver, British Columbia, which strongly suggests a Canadian base. The firm is positioned as a sector investor rather than an operating biotech, with a mandate to provide investors diversified exposure to private psychedelics companies. Its public materials and announcements show an emphasis on early-stage and growth-oriented psychedelic businesses, especially drug development. Origin Therapeutics appears to function as a specialized capital provider in the psychedelic ecosystem, with portfolio updates centered on companies developing psilocybin-based therapies. That makes it relevant as a financing vehicle and visibility source for emerging psychedelic drug programs.

Oscillate PLC is a publicly listed investment company on the Aquis Stock Exchange Growth Market. Its public corporate filings show it is incorporated in England and Wales, with a registered office in London, United Kingdom. Oscillate became relevant to the psychedelic ecosystem after broadening its investment strategy in 2021 to cover medical psychedelics. Public company materials indicate it has held an investment portfolio that included psychedelic-sector opportunities and that the company has been focused on early-stage companies in the space.

Foundation funding psychedelic and mental-health innovation programs, linked to HumanKindLabs initiatives.

Otsuka Pharmaceutical Co., Ltd. is a Japanese pharmaceutical company within the Otsuka group, focused on creating and commercializing medicines and nutraceutical products. Its corporate profile lists its head office in Chiyoda-ku, Tokyo, Japan. The company describes itself as a total healthcare company with global operations and collaboration across academia and venture partners. In the psychedelic ecosystem, Otsuka is relevant because it has moved into adjacent neuropsychiatric and rapid-acting treatment areas through acquisitions and research collaborations. In 2025 it announced a joint research agreement with Keio University on infrastructure development for the social implementation of psychedelics in Japan, and in 2026 it announced and then completed its acquisition of Transcend Therapeutics, whose lead program TSND-201 is described as a rapid-acting neuroplastogen for PTSD.

Palo Santo is a venture capital fund focused on neuroscience and mental health innovation, with an explicit emphasis on next-generation psychedelic therapeutics and enabling technologies. Its public materials describe the firm as investing across novel CNS therapeutics, digital and clinical technologies, and related brain-health infrastructure. The firm is notable in the psychedelic ecosystem because its portfolio includes multiple companies working on psychedelic medicines, serotonergic agonists, ketamine-assisted care, and related CNS drug discovery. Palo Santo also highlights portfolio outcomes such as pharma acquisitions and FDA breakthrough designations across its neuroscience and psychedelic focus areas.

Pancreatic Cancer North America is an IRS-registered 501(c)(3) non-profit dedicated to fighting the world's toughest cancer through research funding, patient support, and awareness initiatives, which has funded a psilocybin-assisted therapy study at Dana-Farber Cancer Institute examining psilocybin's potential to relieve opioid-refractory pain and psychological distress in patients with advanced pancreatic cancer.

The Patient-Centered Outcomes Research Institute (PCORI) is a Washington, DC–based independent non-profit (501(c)(1)) created by the 2010 Affordable Care Act to fund comparative effectiveness research. PCORI awarded $12.6 million to Yale University researchers to directly compare IV racemic ketamine versus intranasal esketamine (Spravato) for treatment-resistant depression, and separately funded the ELEKT-D ketamine vs. ECT effectiveness trial conducted through the Cleveland Clinic Foundation.

Perceptive Advisors is a long-established life sciences investment manager based in New York. Its public materials describe a multi-strategy platform spanning life sciences, credit, capital solutions, and venture capital, with an emphasis on scientific diligence. In psychedelic medicine, Perceptive's role is healthcare-adjacent rather than dedicated. The firm has a confirmed COMPASS Pathways financing record, which supports inclusion without implying that psychedelics are a central thematic focus for the platform.

Peter Thiel is a partner at Founders Fund, a Silicon Valley venture capital firm, and is publicly associated with investing through that platform. Public company materials also identify him as a named investor in atai Life Sciences financing rounds. In the psychedelic ecosystem, Thiel is relevant primarily through atai Life Sciences, a clinical-stage biotech company developing psychedelic and non-psychedelic compounds for mental health indications. atai’s financing announcements describe him as a co-lead investor in the company’s Series C round and as one of the investors in a later convertible note financing.

Phyto Partners is a venture capital firm based in Boca Raton, Florida. Its public materials describe the firm as investing in businesses around cannabis and, more recently, a psychedelic-focused fund called Phyto Psyche. In the psychedelic ecosystem, Phyto Partners matters as one of the earlier cannabis-to-psychedelics crossover investors, with public materials describing an investment thesis around brain health, neurowellness, and psychedelic therapeutics. The firm’s psychedelic content emphasizes a focus on privately held companies and drug-development-oriented opportunities.

Presight Capital is a venture capital fund associated with Christian Angermayer and Apeiron Investment Group. It invests across sectors and stages, with public descriptions indicating a seed-to-growth orientation and a global remit. A public address on the firm’s website places it in West Hollywood, California, United States. Presight matters in the psychedelic ecosystem because it has appeared in the investor syndicate of Delix Therapeutics, a preclinical neuroscience company developing non-hallucinogenic analogs of psychedelics. Public reporting also links Presight to Compass Pathways, making it a visible backer around psychedelic drug development and adjacent neuropsychiatry.

Prime Movers Lab is a venture capital firm and family of funds focused on breakthrough scientific startups, with an emphasis on technically ambitious companies in areas like energy, transportation, infrastructure, manufacturing, human augmentation, and agriculture. Public filings and firm materials place its business in Jackson/Teton Village, Wyoming, in the United States. In the psychedelic ecosystem, Prime Movers Lab is relevant because it has explicitly backed psychedelic medicine and related neuroplasticity work, including Gilgamesh and a participation in Beckley Psytech’s most recent round through an SPV. Its public portfolio and ideas pages also show ongoing attention to psychedelics alongside adjacent neuroscience and biotech themes.

Private Philanthropic Funds is a ClinicalTrials.gov funder category representing anonymous private philanthropic donors, appearing as a collaborator on Johns Hopkins University research including the Phase 1 safety study for at-home administration of microdose psilocybin (NCT06450210). The Psychedelic Science Funders Collaborative (psfc.co) is the leading coordinating body for such private philanthropists dedicated to advancing psychedelic therapy research.

PsyMed Ventures is a venture capital fund focused on brain and mental health innovation, with an explicit emphasis on psychedelic medicine, neurotechnology, precision psychiatry, digital therapeutics, and related frontier technologies. Public sources describe it as San Francisco-based and founded in 2020. In the psychedelic ecosystem, PsyMed Ventures appears as an early-stage backer of companies working across clinical infrastructure, therapeutics, and mental health platforms. Its publicly listed portfolio includes Journey Clinical, Maya Health, Mindstate Design Labs, and Reset Pharma, which places it across both psychedelic care delivery and drug-development-adjacent models.

Psych Capital is a public-market psychedelic investor and media platform built around the medical psychedelics sector. Public filings describe it as the first pure-play psychedelic company to list in London, with an early-stage investment strategy focused on building and growing businesses within psychedelic healthcare. It matters in the psychedelic ecosystem because it combines market coverage, events, and capital allocation around the sector, rather than operating as a generalist fund. Public filings show it has invested in Awakn Life Sciences and has explored further early-stage opportunities in medical psychedelics.

Collaborative funding network coordinating philanthropy and grant strategy for psychedelic science initiatives.

Pura Vida Investments is a New York-based healthcare-focused investment firm and SEC-registered investment adviser that operates as a hedge fund / investment manager. Public sources describe it as market-neutral and oriented toward healthcare and life sciences, with activity across biotech, medical technology, diagnostics, and related therapeutics. In the psychedelic ecosystem, Pura Vida matters mainly as a public-market and crossover healthcare investor rather than a dedicated psychedelics specialist. It has been named in funding rounds for atai Life Sciences, one of the sector’s best-known public psychedelic companies, which suggests exposure to mental-health and psychedelic-adjacent drug development. Public materials place Pura Vida Investments in the New York area and describe it as a healthcare-focused, market-neutral investor with a broad life-science remit. Its publicly visible psychedelic relevance is indirect but meaningful: it has participated in at least one major atai Life Sciences financing, aligning the firm with the public-market side of psychedelic and mental-health therapeutics investing.

QC Ventures is the venture capital investment brand of Q·ADVISERS and describes itself as a deal-by-deal principal investor rather than a traditional fund. Its website says it has historically invested from Seed to Series A and beyond, with the ability to follow on at later stages. QC Ventures has publicly written about psychedelic and adjacent life-science opportunities, including atai Life Sciences and COMPASS Pathways. The firm says it has backed companies with scalable business models across industries and geographies, while also highlighting its role in the psychedelics value chain from research to clinics. The firm is associated with Vienna on its website and is tied to Q·CAPITAL VENTURES GmbH in the site footer, which points to an Austria-based operating presence. Its public materials also describe an active network of co-investors and strategic partners.

RA Capital Management is a large, multi-stage healthcare and life-sciences investment manager that funds and builds companies across a wide development spectrum. Its public materials stress evidence-based investing, company formation, and deep scientific diligence. For psychedelic medicine, RA Capital is relevant because it publicly lists Delix Therapeutics in its venture portfolio and Delix financing materials identify RA as a lead investor in the company's Series A. This is a strong psychedelic-adjacent record, while RA remains best framed as a broad life-sciences investor.

RTW Venture Fund is a life sciences investment vehicle associated with RTW Investments, LP, which describes itself as a New York-based, global, full life-cycle investment firm focused on biopharmaceutical and medical technology innovation. Public RTW materials describe the platform as investing across the lifecycle, including venture, crossover, and public company investments. In the psychedelic ecosystem, RTW Venture Fund appears relevant mainly through adjacent neuropsychiatric and drug-development investing rather than a stated psychedelic-only mandate. RTW has also backed Amani Therapeutics, a company developing a therapy for serious neuropsychiatric disorders, which suggests interest in central nervous system programs that may overlap with psychedelic-adjacent clinical and translational work.

The Rett Syndrome Research Trust (RSRT) is a US-based nonprofit dedicated to curing Rett syndrome (RTT) that funded, held the IND for, and oversaw a randomized double-blind placebo-controlled crossover trial of oral ketamine in girls aged 6-12 with RTT; the study confirmed safety and tolerability and demonstrated EEG evidence of NMDA receptor target engagement, supporting further trials with longer duration or higher doses.

Foundation funding psychedelic science, policy, and education initiatives across the emerging ecosystem.

Roth Capital Partners, LLC is a relationship-driven investment bank serving growth companies and their investors. It is headquartered in Newport Beach, California, with a global trading floor in Stamford, Connecticut. ROTH’s healthcare platform provides financing and strategic advisory services for public and private life sciences companies, including IPOs, follow-on offerings, PIPEs, registered directs, and confidentially marketed public offerings. In the psychedelic ecosystem, that makes it relevant primarily as a capital markets and advisory participant rather than a dedicated psychedelic specialist.

Route 66 Ventures is a private venture capital investor that backs early-stage companies, with a stated focus on digital health and wellness as well as financial technology. Public company information places the firm in Alexandria, Virginia, United States. In the psychedelic ecosystem, Route 66 Ventures is relevant because its portfolio includes Sensorium Therapeutics, a biotechnology company developing nature-inspired psychoactive medicines for mental health. That makes the firm a visible investor in adjacent mental health drug development rather than a generalist consumer or software fund.

The Royal University Hospital Foundation is the charitable fundraising arm of Royal University Hospital in Saskatoon, Saskatchewan, which has invested over $194 million into research, education, and patient care at Saskatchewan's largest academic hospital; the Foundation has supported psychiatry research including ECT and ketamine anesthesia comparative trials and Dr. Evyn Peters' groundbreaking work using intranasal racemic ketamine for hospitalized patients with treatment-resistant depression.

The Quebec Network on Suicide, Mood Disorders and Associated Disorders (RQSHA) is a publicly-funded interdisciplinary research network supported by the Fonds de recherche du Québec that brings together researchers from across Quebec to study suicide, mood disorders, and substance use; it has funded several ketamine trials including the 'Montreal Model' study integrating psychedelic-informed ketamine therapy with psychological support for severe treatment-resistant depression, and research on music as an intervention to improve ketamine tolerability in depression treatment.

The Schulman Research Award is a Canadian research award that has provided funding for clinical anesthesia and psychiatry research; in the psychedelic-adjacent field, it supported a randomized study at the University of Saskatchewan comparing ketamine-based versus propofol-based anesthesia for electroconvulsive therapy (ECT) in patients with treatment-resistant major depressive disorder, which found that ketamine-based anesthesia resulted in superior treatment outcomes on the Montgomery-Åsberg Depression Rating Scale.

The Swiss National Science Foundation (Schweizerischer Nationalfonds, SNF) is Switzerland's principal public funder of scientific research across all academic disciplines; in the psychedelic field, it has funded multiple clinical trials including psilocybin studies for alcohol use disorder and major depressive disorder, contributing to Switzerland's position as the world's second-largest hub for psychedelic clinical research with over 35 trials and a historic connection to Albert Hofmann's discovery of LSD and isolation of psilocybin at Basel.

The Special Operations Care Fund (SOC-F) is a US non-profit organization based in Atlanta, Georgia, that provides direct support to active and retired members of the Special Operations Forces community and their families. It is the sponsor of the Trifecta Research Study — conducted with Johns Hopkins Center for Psychedelic and Consciousness Research — which investigates hormone replacement therapy, magnetic e-resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in combination for the treatment of PTSD and TBI-related cognitive impairment in SOF veterans.

Private foundation with publicly documented support for psychedelic and mental-health research initiatives.

Stifel is a U.S.-based diversified wealth management and investment banking firm with a corporate headquarters in St. Louis, Missouri. It serves individuals, institutions, and corporations through brokerage, research, investment banking, and related financial services. In the psychedelic ecosystem, Stifel is mainly relevant as a healthcare and biopharma capital-markets participant rather than a dedicated psychedelic specialist. Its public materials show active coverage of life sciences and biopharma, including venture banking and capital-raising activity in the sector, which makes it a potential advisor or financing counterparty for psychedelic drug developers as they move through public and late-stage markets.

Subversive Capital is a New York-based investment firm that operates across venture investing, public markets, activism, whistleblower financing, and ETFs. Public filings and the firm’s site describe it as active in early- and late-stage investments, with a focus on companies that operate in highly regulated or category-defining sectors. In the psychedelic ecosystem, Subversive is relevant because it has participated in atai Life Sciences financing rounds, including atai’s Series D in 2021. Its public positioning and board-level involvement with atai suggest a broader interest in regulated mental health and psychedelic-adjacent opportunities.

The SNSF funds basic and applied research across Switzerland. Funds notable psychedelic research at Swiss universities and hospitals (Basel, Zurich, Geneva).

Tabula Rasa Ventures is a venture capital firm focused on investing in health-related companies, including drug development, healthcare infrastructure, and digital therapeutics. Its website and profiles describe it as an early-stage investor with activity from pre-seed and seed through growth-stage financing. Public-facing sources point to New York, New York, in the United States as its base of operations. It matters in the psychedelic ecosystem because Tabula Rasa has explicitly backed psychedelic companies and frames part of its work around psychedelic and psychedelic-adjacent entrepreneurship. Its portfolio page includes Lykos Therapeutics and Natural MedTech, both tied to psychedelic drug development and research, and the firm has also described itself as supporting a psychedelic business incubator.

The state public health agency for Texas, responsible for promoting and protecting the health of Texans through disease prevention, health promotion, and oversight of public health services. The agency licenses healthcare facilities, monitors communicable diseases, and supports mental health and substance use programs.

Texas state health agency overseeing policy functions and implementation of psychedelic-adjacent public initiatives such as ibogaine programs.

The philanthropic vehicle of the Council on Spiritual Practices (CSP), administered as Fund #4745 within the San Francisco Foundation. CSP is a nonprofit organization that played a foundational role in supporting psilocybin research at Johns Hopkins University, including landmark studies on mystical experience, spiritual practice, and the therapeutic potential of psychedelics.

The Conscious Fund is a venture capital adviser and fund focused on early-stage psychedelic medicine and adjacent therapeutic innovation. Its public materials describe the firm as backing pioneers of psychedelic medicine, state of mind, and advanced therapeutics, and an SEC Form ADV identifies its legal entity as TCF Management LLC. The firm’s relevance in the psychedelic ecosystem comes from its explicit specialization in psychedelic medicine and its role as an early-stage investor in the sector. Public materials also indicate a global investment lens, with the firm describing itself as investing in global early-stage ventures in psychedelic medicine.

Czech philanthropic foundation supporting research and public education initiatives related to psychedelics.

Named fellowship program supporting journalism capacity around psychedelic science and policy.

A nonprofit organization based in San Anselmo, California, dedicated to advancing the therapeutic use of ketamine and psychedelic medicines. Founded by Dr. Phil Wolfson, the Ketamine Research Foundation conducts FDA-approved clinical research on ketamine-assisted psychotherapy, operates the premier Ketamine Training Center, and maintains a comprehensive scholarly library on ketamine therapeutics.

Named endowed-funding initiative supporting sustained psychedelic science leadership at Johns Hopkins.

The Wallace Foundation is a US national philanthropy that funds research and practice in education, arts, and youth development. The foundation supports programs that expand learning opportunities for disadvantaged young people and strengthen cultural organizations. Its presence in clinical research records may reflect its growing interest in youth mental health and social-emotional learning initiatives.

Entrepreneur and donor included in psychedelic-focused philanthropy mappings; public recipient-level detail is currently limited.

Tim Ferriss is a U.S.-based angel investor, author, and podcast host who has been angel investing in tech and consumer packaged goods startups since 2008. His own site describes him as an early-stage technology investor/advisor and notes that most of his portfolio investments have been seed or Series A, with some later-stage positions. He matters in the psychedelic ecosystem because he has publicly backed psychedelic research and funding efforts, including major support for MDMA-assisted therapy and Johns Hopkins’ psychedelic research center. His public writing also says he shifted most of his focus away from startup investing and toward psychedelic science in 2015.

Foundation supporting mental-health and psychedelic-adjacent initiatives with explicit wellbeing and societal impact framing.

Transform Drug Policy Foundation is a UK-based independent charity that works nationally and internationally on drug policy reform. Its main audience includes policymakers, the public, governments, and practitioners, and its core work is public education, policy analysis, and promoting legal regulation models for currently illegal drugs. In psychedelic policy, Transform is clearly active and has published guidance on how to regulate psychedelics, with a focus on non-medical adult use and broader legal frameworks. Its work also emphasizes equity, Indigenous rights, corporate capture mitigation, and international treaty questions, making it relevant to policy groups, researchers, funders, and community stakeholders interested in regulated access and drug law reform.

U.S. Army medical R&D command supporting military biomedical research and administration pathways connected to DoD psychedelic clinical trial funding.

U.S. federal veterans health authority with explicit psychedelic-adjacent clinical research and care-implementation activity through VA research and care networks.

UKRI is the UK government's research funding body. Includes the Medical Research Council (MRC) and Engineering and Physical Sciences Research Council (EPSRC), both relevant to psychedelic and related research.

ARPA-H is the US federal agency for high-risk, high-reward biomedical research. Launched the EVIDENT initiative in 2025 (total $139.4M, ≥$50M earmarked for psychedelic research for serious mental illness) to validate and innovate behavioral-health therapeutics including psilocybin and related compounds.

The NSF funds basic science research across the US, including neuroscience and pharmacology projects relevant to psychedelic mechanisms.

Federal defense department overseeing military health R&D and psychedelic-related clinical trial funding via DHA/DMRDP implementation.

Naval Medical Center San Diego (NMCSD) is the US Navy’s largest hospital on the West Coast, providing medical care to active-duty military personnel, retirees, and their families. Its Department of Psychiatry participates in clinical trials investigating MDMA-assisted and psilocybin-assisted therapies for PTSD and depression in service members, contributing to the DoD’s expanding psychedelic research program.

The VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.

U.S. Veterans Affairs research authority overseeing national veteran-focused clinical research programs including psychedelic-adjacent initiatives.

The VA Puget Sound Health Care System serves veterans across the Pacific Northwest with major facilities in Seattle and Tacoma, Washington. As part of the VA’s expanding psychedelic research program, it participates in clinical trials examining MDMA-assisted therapy and psilocybin for PTSD and depression in veterans.

A nonprofit philanthropic organization dedicated to supporting Vail Health and its affiliated behavioral health programs in Eagle County, Colorado. The Vail Health Foundation generates philanthropy for Shaw Cancer Center, Eagle Valley Behavioral Health, and allied community nonprofits, with a $100 million campaign focused on transforming behavioral health care across mountain communities.

Vancouver Island Health Authority (Island Health) is a publicly funded regional health authority serving Vancouver Island and surrounding communities in British Columbia, Canada. Island Health operates hospitals, mental health services, and community health programs for over 800,000 residents, and supports clinical research including innovative approaches to psychedelic-assisted mental health treatment.

Västra Götalandsregionen (Region Västra Götaland) is the regional government and public health authority for western Sweden, including the Gothenburg metropolitan area and surrounding counties. With 1.7 million residents served by 17 hospitals and over 50,000 employees, it is one of Sweden's largest public employers and a major supporter of clinical psychiatric research.

Venrock Healthcare Capital Partners (VHCP) is Venrock’s later-stage healthcare investing program, focused on publicly held and late-stage private healthcare companies. Venrock is a venture capital firm founded in 1969, and public Venrock materials describe VHCP as a public and cross-over biotech fund. The firm’s team is based across Palo Alto and New York, with Venrock also operating in Boston. VHCP matters to the psychedelic ecosystem mainly as a broader life-sciences and drug-development investor rather than a dedicated psychedelics fund. Venrock’s public materials emphasize biotechnology, pharmaceuticals, and crossover/public healthcare investing, with team members who have experience across the full drug-development arc and in neurodegenerative disease programs.

Vine Ventures is an early-stage venture capital firm that describes its work as focused on health and wellness, with a particular interest in psychedelics, mental health, consciousness, and related life sciences themes. The firm says it was started in 2020 and operates with a presence in New York City and Tel Aviv. In the psychedelic ecosystem, Vine has positioned itself as a backer of companies and initiatives tied to psychedelic therapies and adjacent mental health models. Its public materials say it has led a large financing vehicle for MAPS to help bring MDMA to market for PTSD and that its team publishes and hosts content around psychedelic science and distribution.

Walter Reed National Military Medical Center (WRNMMC) is the United States' premier military medical center, located in Bethesda, Maryland and operated jointly by the Army and Navy. It provides advanced medical care to active duty service members, veterans, retirees, and their families, and conducts clinical research on PTSD, traumatic brain injury, and emerging treatments for military personnel.

What If Ventures is a venture capital firm founded in 2020 and based in Frisco, Texas, United States. It invests from seed through pre-IPO and describes itself as focused on health, freedom, mental health, and disruptive healthcare, with some portfolio exposure to psychedelic and adjacent mental health companies. In the psychedelic ecosystem, What If Ventures matters because its portfolio includes companies such as Atai Life Sciences, Beckley Psytech, and 2A Biosciences, all of which are publicly associated with psychedelic medicine or psychedelic-adjacent drug development. The firm’s public portfolio and team pages show continued interest in mental health innovation, addiction, biomarkers, and psychiatric drug development.

The World Health Organization (WHO) is the United Nations' specialized agency for international public health, founded in 1948 and headquartered in Geneva, Switzerland. WHO sets global health standards, coordinates disease surveillance, and provides technical guidance on mental health, substance use disorders, and the international scheduling of controlled substances including psychedelics.

Y Combinator is a startup accelerator and venture investor founded in 2005. It is based in San Francisco, California, and also lists Mountain View, California as a location on its public company profile. YC funds companies across software and biotech, and says it is especially comfortable funding life science projects at their earliest stage. In its current public biotech and drug-discovery materials, YC highlights work ranging from therapeutics to mental health and psychedelic medicine-adjacent companies.

ZonMw (The Netherlands Organisation for Health Research and Development) is a Dutch government organization that funds and steers health research and healthcare innovation on behalf of the Ministry of Health, Welfare and Sport and the Dutch Research Council (NWO). ZonMw finances studies across all healthcare domains including mental health, substance use disorders, and novel therapeutic approaches such as psychedelic-assisted therapy.

Corporate philanthropy initiative launched by atai to support equitable mental-health innovation and psychedelic ecosystem programs.

atai-funded fellowship program in psychedelic neuroscience supporting trainee and early-career researchers.

re.Mind Capital is a venture capital fund focused on mental health, brain health, and human flourishing, with a public website that lists its office in London and a Maltese company footer. Its site also describes it as a leading early-stage investor, and its legal pages identify re.Mind Capital Limited with an address in Sliema, Malta. In the psychedelic ecosystem, re.Mind matters because its public stories and investment context show activity across brain-computer interfaces and psychedelic-related therapeutics, including a featured story about Delix and a story page highlighting Small Pharma. Public references also describe the fund as part of Christian Angermayer’s Apeiron ecosystem and as an investor in psychedelic medicine alongside other neurotechnology and mental health themes.